ProMIS Neurosciences (NASDAQ:PMN – Get Free Report) is expected to release its earnings data on Monday, March 24th. Analysts expect ProMIS Neurosciences to post earnings of ($0.14) per share for the quarter.
ProMIS Neurosciences Stock Performance
Shares of NASDAQ:PMN opened at $0.65 on Friday. The company has a market capitalization of $21.08 million, a PE ratio of -6.45 and a beta of 0.58. The company’s fifty day moving average is $0.85 and its 200-day moving average is $0.98. ProMIS Neurosciences has a 52 week low of $0.62 and a 52 week high of $2.61.
Wall Street Analyst Weigh In
Separately, Guggenheim reaffirmed a “buy” rating on shares of ProMIS Neurosciences in a report on Wednesday, February 26th.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Featured Stories
- Five stocks we like better than ProMIS Neurosciences
- What is a Special Dividend?
- MarketBeat Week in Review – 03/17 – 03/21
- 3 Monster Growth Stocks to Buy Now
- FedEx Delivers Another Crushing Blow to Its Stock Price
- What is Insider Trading? What You Can Learn from Insider Trading
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
